Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Difelikefalin in Atopic Dermatitis Pruritus
NCT05387707Phase 3Terminated
- Sponsor
- Cara Therapeutics, Inc.
- Start
- Aug 2022
- Primary completion
- Feb 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of difelikefalin in atopic dermatitis (AD), sponsored by Cara Therapeutics, Inc.. Started Aug 2022; status: terminated.
02
Drugs
difelikefalin
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05387707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387707.